Deferoxamine Mesylate interactions
Checked as Deferoxamine in this data source.
Full monograph for Deferoxamine MesylateCheck it against another medicine
Medicines
72 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Iodixanol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iohexol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iopamidol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Tenofovir Alafenamide | Major | Excretion | Coadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally… | 8 sources — open the full entry |
| Tenofovir Disoproxil | Major | Excretion | Coadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally… | 8 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfate | Moderate | Others · Unknown | Although ascorbic acid is commonly given during deferoxamine treatment, cardiac disorders (left ventricular dysfunction) and cataracts have been reported with…2 documented mechanisms | 2 sources — open the full entry |
| Prochlorperazine Maleate | Moderate | Others | Limited data suggest that the concomitant administration of deferoxamine and prochlorperazine may result in transient metabolic encephalopathy. The mechanism… | 2 sources — open the full entry |
| Remdesivir | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Vitamin C [Ascorbic acid] | Moderate | Others | Although ascorbic acid is commonly given during deferoxamine treatment, cardiac disorders (left ventricular dysfunction) and cataracts have been reported with… | 2 sources — open the full entry |
Conditions
Conditions in which Deferoxamine Mesylate needs care, as documented in this source.
Kidney Diseases
MajorThe use of deferoxamine is contraindicated in patients with severe renal impairment or anuria. Deferoxamine chelates iron and the complexes are primarily eliminated by the kidney.
1 source
- "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals (2001):
Auditory Diseases, Central
ModerateNeurotoxicity-related auditory abnormalities such as tinnitus and hearing loss including deafness have occurred after prolonged therapy or large doses of deferoxamine, or in patients with low ferritin levels. Therapy with deferoxamine should be administered cautiously in patients with hearing impairment. Hearing toxicity is usually reversible if detected early and deferoxamine discontinued.
1 source
- "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals (2001):
Hepatic Insufficiency
ModerateNo studies of deferoxamine have been performed in patients with hepatic impairment. Caution is advised.
1 source
- "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals (2001):
Respiratory Distress Syndrome
ModerateAcute respiratory distress syndrome has been described in patients with acute iron intoxication or thalassemia following treatment with excessively high intravenous doses of deferoxamine. Caution is recommended when using deferoxamine in these patients.
1 source
- "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals (2001):
Toxic Optic Neuropathy
ModerateDeferoxamine may cause blurred vision, cataracts, decreased visual acuity, and impaired color, peripheral, and night vision. Ocular toxicities have occurred after prolonged therapy, large doses, and in patients with decreased ferritin levels. Therapy with deferoxamine should be administered cautiously in patients with or predisposed to visual defects. Periodic examination of visual acuity is recommended in patients receiving long term deferoxamine therapy. Ocular dysfunction is usually reversible if detected early and deferoxamine is withdrawn promptly.
1 source
- "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals (2001):